British Journal of Clinical Pharmacology

Uncertain risks of drug related harms, the precautionary principle and limitations of meta-analysis
pp. 647-650(4)
Author: Ritter, JM

Maraviroc and raltegravir
pp. 651-652(2)
Authors: Dubois, Eline A.; Cohen, Adam F.

Aliskiren
pp. 653-654(2)
Authors: Dubois, Eline A.; Cohen, Adam F.

Effect of topiramate on acid-base balance: extent, mechanism and effects
pp. 655-661(7)
Authors: Mirza, Nasir; Marson, Anthony G.; Pirmohamed, Munir

The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trial
pp. 662-668(7)
Authors: Dawson, Jesse; Quinn, Terrence J.; Harrow, Craig; Lees, Kennedy R.; Walters, Matthew R.

Population pharmacokinetic analysis of varenicline in adult smokers
pp. 669-681(13)
Authors: Ravva, Patanjali; Gastonguay, Marc R.; Tensfeldt, Thomas G.; Faessel, Hélène M.

Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite
pp. 682-689(8)
Authors: Damle, Bharat D.; Uderman, Howard; Biswas, Pinaki; Crownover, Penelope; Lin, Chang; Glue, Paul

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
pp. 690-699(10)
Authors: Mukonzo, Jackson K.; Röshammar, Daniel; Waako, Paul; Andersson, Maria; Fukasawa, Takashi; Milani, Lili; Svensson, Jan Olof; Ogwal-Okeng, Jasper; Gustafsson, Lars L.; Aklillu, Eleni

Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events
pp. 700-711(12)
Authors: Barras, Michael A.; Duffull, Stephen B.; Atherton, John J.; Green, Bruce

Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole
pp. 712-720(9)
Authors: Grün, Barbara; Krautter, Stefanie; Riedel, Klaus-Dieter; Mikus, Gerd

Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion
pp. 721-730(10)
Authors: He, Xi; Hesse, Leah M.; Hazarika, Suwagmani; Masse, Gina; Harmatz, Jerold S.; Greenblatt, David J.; Court, Michael H.

Inhaled tiotropium bromide and risk of stroke
pp. 731-736(6)
Authors: Grosso, Anthony; Douglas, Ian; Hingorani, Aroon D.; MacAllister, Raymond; Hubbard, Richard; Smeeth, Liam

Albendazole and its metabolites in the breast milk of lactating women following a single oral dose of albendazole
pp. 737-742(6)
Authors: Abdel-tawab, Ahmed M.; Bradley, Mark; Ghazaly, Essam A.; Horton, John; El-Setouhy, Maged

Sudden death in patients receiving drugs tending to prolong the QT interval
pp. 743-751(9)
Authors: Jolly, Kate; Gammage, Michael D.; Cheng, Kar Keung; Bradburn, Peter; Banting, Miriam V.; Langman, Michael J. S.

Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study
pp. 752-764(13)
Authors: Wheeler, Benedict W.; Metcalfe, Chris; Gunnell, David; Stephens, Peter; Martin, Richard M.

Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies
pp. 765-769(5)
Authors: Tesmoingt, Chloe; Lidove, Olivier; Reberga, Axele; Thetis, Marguerite; Ackaert, Chloe; Nicaise, Pascale; Arnaud, Philippe; Papo, Thomas

Characterization of a novel TPMT mutation associated with azathioprine-induced myelosuppression
pp. 770-772(3)
Authors: de Beaumais, Tiphaine Adam; Fakhoury, May; Pigneur, Benedicte; Viola, Sheila; Medard, Yves; Broly, Franck; Jacqz-Aigrain, Evelyne

The impact of clinical trials legislation on clinical pharmacology: problems and solutions
pp. 773-774(2)
Author: Wells, Frank

Circles of Hell: researchers' nightmare or laps of the regulatory pentathlon?
pp. 775-777(3)
Author: Brown, Morris

Reply to Frank Wells' letter
pp. 778-778(1)
Author: Ritter, James M.

Frontiers of Neurology and Neuroscience
pp. 779-779(1)

John Feely: MD, MA, BSC, FRCPE, FRCPI, FFPHMI (Hon)
pp. 780-781(2)
Authors: Routledge, Phil; Williams, David

ABSTRACTS OF THE DUTCH SOCIETY OF CLINICAL PHARMACOLOGY AND BIOPHARMACY MEETING OF MARCH 27 2009
pp. 782-793(12)

Translation Section
pp. 794-799(6)